Meeting
2015 ASCO Annual Meeting
Protein activation mapping and exploratory predictive markers for pCR in triple-negative breast cancer patients treated with neratinib in the I-SPY 2 TRIAL.
Authors
Julia Dianne Wulfkuhle
George Mason Univ, Columbia, MD
Julia Dianne Wulfkuhle , Christina Yau , Denise M Wolf , Rosa Isela Gallagher , Jianghong Deng , Lamorna Brown Swigart , Gillian Hirst , Minetta C. Liu , John W. Park , Laura Esserman , Donald A. Berry , Laura van't Veer , Emanuel Petricoin III
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01042379
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1085)
DOI
10.1200/jco.2015.33.15_suppl.1085
Abstract #
1085
Poster Bd #
199
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Preclinical studies with neratinib in triple-negative breast cancer.
First Author: Maeve Mullooly
Poster
2013 ASCO Annual Meeting
Molecular biomarkers as predictive factors of pCR for early triple-negative breast cancer.
First Author: Ismael Ghanem
Poster
2017 ASCO Annual Meeting
Individualized screening trial of innovative glioblastoma therapy (INSIGhT).
First Author: Brian Michael Alexander
Poster
2016 ASCO Annual Meeting
Androgen receptor (AR) expression in primary breast cancer (BC): Correlations with clinical characteristics and outcomes.
First Author: Neelima Vidula